# Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

> **NCT07337551** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guiying Wang** · enrollment: 20 (estimated)

## Conditions studied

- Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment

## Interventions

- **DRUG:** Gossypol acetate Combined with Bevacizumab and FOLFIRI

## Key facts

- **NCT ID:** NCT07337551
- **Lead sponsor:** Guiying Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07337551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07337551, "Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07337551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*